C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart I—Laboratory Controls

21 C.F.R. § 211.166 (2026)

Stability testing

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1984–2010 7citing cases

(a) There shall be a written testing program designed to assess the stability characteristics of drug products. The results of such stability testing shall be used in determining appropriate storage conditions and expiration dates. The written program shall be followed and shall include:

(1) Sample size and test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability;

(2) Storage conditions for samples retained for testing;

(3) Reliable, meaningful, and specific test methods;

(4) Testing of the drug product in the same container-closure system as that in which the drug product is marketed;

(5) Testing of drug products for reconstitution at the time of dispensing (as directed in the labeling) as well as after they are reconstituted.

(b) An adequate number of batches of each drug product shall be tested to determine an appropriate expiration date and a record of such data shall be maintained. Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted. Where data from accelerated studies are used to project a tentative expiration date that is beyond a date supported by actual shelf life studies, there must be stability studies conducted, including drug product testing at appropriate intervals, until the tentative expiration date is verified or the appropriate expiration date determined.

(c) For homeopathic drug products, the requirements of this section are as follows:

(1) There shall be a written assessment of stability based at least on testing or examination of the drug product for compatibility of the ingredients, and based on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.

(2) Evaluation of stability shall be based on the same container-closure system in which the drug product is being marketed.

(d) Allergenic extracts that are labeled “No U.S. Standard of Potency” are exempt from the requirements of this section.

[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981]
The 7 cases that cite 21 C.F.R. § 211.166 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. Baxter Healthcare Corp., 901 F.2d 1401 (7th Cir. 1990).
cites § 211.166 2×cited by 35 cases
Where it cites § 211.166
“In defending its use of its own studies in determining whether to freeze drug products and for what time period, Baxter refers to 21 C.F.R. § 211.166 , which requires that manufacturers perform and maintain data concerning stability testing.”
Later courts cite it for
“an administrative agency's interpretations of congressional acts, and even more so of its own regulations, are due great deference.” · 2 citing courts
2
GREENJones v. State, 170 Wash. 2d 338 (2010).
cites § 211.166 1×cited by 26 cases
Where it cites § 211.166
“§ 321 ; 21 C.F.R. § 211.166 . ¶81 Inspector Jeppesen’s report following the July 1999 inspection states that 38 items in Jones’s prescription stock area were outdated.”
3
cites § 211.166 1×cited by 13 cases
Where it cites § 211.166
“137 , is related to the requirements of 21 C.F.R. § 211.166 , which mandate that manufacturers perform the necessary testing to determine the stability of the drug and its components, and the point in time after which it may be subject to deterioration and loss of effectiveness…”
Later courts cite it for
“sufficiently definite and precise to comport with constitutional standards and are not arbitrary or capricious on grounds of vagueness.” · 2 citing courts
4
GREENUnited States v. Richlyn Labs., Inc., 827 F. Supp. 1145 (E.D. Pa. 1992).
cites § 211.166 1×cited by 12 cases
Where it cites § 211.166
“21 C.F.R. § 211.166 . Finally, the regulations mandate that any building(s) used in the manufacture, processing, packing or holding of drug products be constructed and maintained in such a way as “to prevent mix-ups between different components, drug product containers,…”
Later courts cite it for
“indeed, because congress has seen fit to act in a given area by enacting a statute, irreparable injury must be presumed in a statutory enforcement action.” · 2 citing courts
5
GREENBelmac Hygiene, Inc. v. Belmac Corp., 121 F.3d 835 (2d Cir. 1997).
cites § 211.166 1×cited by 7 cases
Where it cites § 211.166
“In addition to these written misrepresentations, the district court correctly found that Cohen made several false statements about the existence of a qualified manufacturer to produce Lotus 24.”
6
GREENUnited States v. Richlyn Labs., Inc., 822 F. Supp. 268 (E.D. Pa. 1993).
cites § 211.166 1×cited by 6 cases
Where it cites § 211.166
“21 C.F.R. § 211.166 . Finally, the regulations mandate that any building(s) used in the manufacture, processing, packing or holding of drug products be constructed and maintained in such a way as “to prevent mix-ups between different components, drug product containers,…”
7
GREENJones v. State, Dept. of Health, 242 P.3d 825 (Wash. 2010).
cites § 211.166 1×cited by 3 cases
Where it cites § 211.166
“§ 321 ; 21 C.F.R. § 211.166 . ¶ 81 Inspector Jeppesen's report following the July 1999 inspection states that 38 items in Jones's prescription stock area were outdated.”
The case’s holding
A final agency action is a definitive act that remains binding unless set aside by a court.
Later courts cite it for
“a final agency action 'implies a definitive act of the agency, action which is binding until and unless it is set aside by a court.” · 3 citing courts

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198419972010

One bar per year. Tallest: 2 cases in 2010. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
E.D. Pa.2Wash.22d Cir.17th Cir.1S.D.N.Y.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com